Anti-BQ antibody
Anti-BQ (BQ323636.1) antibody, clone D12
Overview
Western blot
(primary antibody: anti-BQ 1:500;
secondary antibody: anti-mouse 1:2,000)
Arrow indicates the target band.
Breast cancer is the most common female cancer. About 70% of breast cancer is estrogen receptor positive (ER+). Tamoxifen is an effective and common drug for adjuvant treatment. However, up to 50% of the ER+ breast cancer eventually develop resistance to tamoxifen. A robust biomarker that can reliably predict which cancers will develop tamoxifen resistance is of particular importance. BQ323636.1 is a splice variant of NCOR2 [1]. It contains 362 amino acids with a molecular mass 42.6 kDa. The detection of nuclear overexpression of BQ323636.1 by immunohistochemistry (IHC) in primary breast tumors was found to be strongly associated with the development of tamoxifen resistance (p=1.79 x 10-6; sensitivity: 52.9%, specificity: 72.0%) [2]. The antibody may be used in the clinical setting for predicting tamoxifen response of ER+ breast cancer patients.
IHC
| Anti-BQ (BQ323636.1) antibody, clone D12 | |
|---|---|
| Product name | Anti-BQ (BQ323636.1) antibody, clone D12 |
| Description | Mouse monoclonal antibody against BQ323636.1 is an affinity purified mouse immunoglobulin, IgG1, which specifically recognizes the unique epitope of the BQ323636.1 protein. BQ323636.1 is a novel alternatively spliced isoform of human NCOR2. Monoclonal anti-BQ antibody is useful for detection of BQ323636.1 proteins by immunohistochemistry (IHC) on formalin-fixed paraffin embedded (FFPE) sections; immunofluorescence (IF); and western blot. |
| Tested applications | IHC; IF; western blot |
| Species reactivity | Human |
| Immunogen | QRTWRSRCASWP |
| Purification and storage |
Protein G purification (purity ≥ 90%). Store the antibody in 2°C to 8°C. Avoid freezing. Supplied at 1 mg/ml in phosphate buffered saline, pH7.4, with 0.05% sodium azide and 0.5% albumin. |
| Recommended dilutions |
IHC 1:50 IF 1:50 Western blot 1:500 |
For Research Use Only. Not for diagnostic or therapeutic use.
References
- Zhang LD, Gong C, Lau SLY, et al. SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of NCOR2/SMRT That Is Associated with Tamoxifen Resistance and Control of ER alpha Transcriptional Activity. Cancer Research 2013;73(1):246-255
- Gong C, Man EPS, Tsoi H, et al. BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research 2018;24(15):3681-3691
